Abstract:The histopathological subtype of lung adenocarcinoma (LUAD) is closely associated with prognosis. Micropapillary or solid predominant LUAD tends to relapse after surgery at an early stage, whereas lepidic pattern shows a favorable outcome. However, the molecular mechanism underlying this phenomenon remains unknown. Here, we recruited 31 lepidic predominant LUADs (LR: low-risk subtype group) and 28 micropapillary or solid predominant LUADs (HR: high-risk subtype group). Tissues of these cases were obtained and label-free quantitative proteomic and bioinformatic analyses were performed. Additionally, prognostic impact of targeted proteins was validated using The Cancer Genome Atlas databases (n=492) and tissue microarrays composed of early-stage LUADs (n=228). A total of 192 differentially expressed proteins were identified between tumor tissues of LR and HR and three clusters were identified via hierarchical clustering excluding eight proteins. Cluster 1 (65 proteins) showed a sequential decrease in expression from normal tissues to tumor tissues of LR and then to HR and was predominantly enriched in pathways such as tyrosine metabolism and ECM-receptor interaction, and increased matched mRNA expression of 18 proteins from this cluster predicted favorable prognosis. Cluster 2 (70 proteins) demonstrated a sequential increase in expression from normal tissues to tumor tissues of LR and then to HR and was mainly enriched in pathways such as extracellular organization, DNA replication and cell cycle, and high matched mRNA expression of 25 proteins indicated poor prognosis. Cluster 3 (49 proteins) showed high expression only in LR, with high matched mRNA expression of 20 proteins in this cluster indicating favorable prognosis. Furthermore, high expression of ERO1A and FEN1 at protein level predicted poor prognosis in early-stage LUAD, supporting the mRNA results. In conclusion, we discovered key differentially expressed proteins and pathways between low-risk and high-risk subtypes of early-stage LUAD. Some of these proteins could serve as potential biomarkers in prognostic evaluation.

Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma

A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Proteomic biomarkers for lung cancer progression

Integrative Proteomic Characterization of Human Lung Adenocarcinoma

Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma

Quantitative proteomics identified circulating biomarkers in lung adenocarcinoma diagnosis

Combining Genetic Mutation and Expression Profiles Identifies Novel Prognostic Biomarkers of Lung Adenocarcinoma.

Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model

Identification of Pivotal Genes with Prognostic Evaluation Value in Lung Adenocarcinoma by Bioinformatics Analysis

Discovery of a Set of Biomarkers of Human Lung Adenocarcinoma Through Cell-Map Proteomics and Bioinformatics

Immune, metabolic landscapes of prognostic signatures for lung adenocarcinoma based on a novel deep learning framework

The Screening of Immune-Related Biomarkers for Prognosis of Lung Adenocarcinoma

A Prognostic Signature Model for Unveiling Tumor Progression in Lung Adenocarcinoma

Proteomic Analyses Identify Differentially Expressed Proteins and Pathways Between Low-Risk and High-Risk Subtypes of Early-Stage Lung Adenocarcinoma and Their Prognostic Impacts.

A Novel Prognostic Model of Early-Stage Lung Adenocarcinoma Integrating Methylation and Immune Biomarkers

Trans-omics Biomarker Model Improves Prognostic Prediction Accuracy for Early-Stage Lung Adenocarcinoma.

Machine Learning-Based Immune Prognostic Model and Cerna Network Construction for Lung Adenocarcinoma

5-Mrna-based Prognostic Signature of Survival in Lung Adenocarcinoma